Osteoclast Activation in Multiple Myeloma

2010 ◽  
pp. 183-198
Author(s):  
Sonia Vallet ◽  
Noopur Raje
Keyword(s):  
Multiple Myeloma ◽  
Osteoclast Activation

scholarly journals 663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma

2006 ◽  
Vol 13 ◽  
pp. S256 ◽  
Author(s):  
Neil Rabin ◽  
Chara Kyriakou ◽  
Arnold Pizzey ◽  
Clive Buckle ◽  
Matthew Prideaux ◽  
...  
Keyword(s):  
Stem Cells ◽  
Multiple Myeloma ◽  
Mesenchymal Stem Cells ◽  
Murine Model ◽  
Human Mesenchymal Stem Cells ◽  
Osteoclast Activation

scholarly journals Notch inhibition blocks multiple myeloma cell-induced osteoclast activation

Leukemia ◽  
2008 ◽  
Vol 22 (12) ◽  
pp. 2273-2277 ◽  
Author(s):  
R Schwarzer ◽  
M Kaiser ◽  
O Acikgoez ◽  
U Heider ◽  
S Mathas ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Myeloma Cell ◽  
Multiple Myeloma Cell ◽  
Notch Inhibition ◽  
Osteoclast Activation

Proteasome inhibitors as therapeutics

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson
Keyword(s):  
Multiple Myeloma ◽  
Drug Class ◽  
Proteasome Inhibitors ◽  
Cell Cycle Regulators ◽  
Current State ◽  
Intracellular Mechanism ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway ◽  
Hodgkin's Lymphomas ◽  
Clinical Research Data

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.

Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Protein Expression ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Bone Sialoprotein ◽  
Multiple Myeloma Cell ◽  
Human Multiple Myeloma ◽  
Mrna And Protein Expression

Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma

2000 ◽  
Vol 111 (1) ◽  
pp. 381-381 ◽  
Author(s):  
C. W. Tiplady ◽  
G. P. Summerfield
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Refractory Multiple Myeloma

Controversies surrounding the clonogenic origin of multiple myeloma

2000 ◽  
Vol 110 (1) ◽  
pp. 240-241 ◽  
Author(s):  
Faith E. Davies ◽  
Andrew C. Rawstron ◽  
Roger G. Owen ◽  
Gareth J. Morgan
Keyword(s):  
Multiple Myeloma

Sturge-Weber syndrome and multiple myeloma

1969 ◽  
Vol 100 (4) ◽  
pp. 488b-488
Author(s):  
H. O. Curth
Keyword(s):  
Multiple Myeloma ◽  
Weber Syndrome ◽  
Sturge Weber Syndrome

Value of FDG PET in the Assessment of Patients With Multiple Myeloma

2006 ◽  
Vol 2006 ◽  
pp. 178-181
Author(s):  
E. Glatstein
Keyword(s):  
Multiple Myeloma ◽  
Fdg Pet
Sign in / Sign up

Export Citation Format

Share Document